Welcome to our dedicated page for Iridex news (Ticker: IRIX), a resource for investors and traders seeking the latest updates and insights on Iridex stock.
Iridex Corporation develops, manufactures, and markets laser-based medical systems, delivery devices, procedure probes, accessories, and consumable instrumentation for ophthalmology. Its products support treatment of glaucoma, diabetic macular edema, and other retinal diseases, with proprietary MicroPulse® technology used across parts of its portfolio.
Iridex news commonly covers quarterly and annual financial results, business updates, product-family activity for systems such as Cyclo G6®, retina laser platforms including PASCAL®, IQ 532®, IQ 577®, and OcuLight® TX, and clinical literature involving MicroPulse transscleral laser therapy. Company updates also address commercial partnerships, U.S. direct sales, international distributor activity, operational efficiency measures, and Nasdaq listing-status matters.
Iridex (NASDAQ: IRIX) reported third quarter 2025 results with revenue of $12.5M, up 8% year‑over‑year, driven by higher Cyclo G6 probe and Pascal retina system sales.
Key metrics: Cyclo G6 revenue $3.5M (+13%), retina revenue $6.7M (+4%), gross profit $4.0M (32.1% margin), operating expenses $5.4M (down 12%), adjusted EBITDA loss $0.131M (improved $1.3M), and cash $5.6M (down $1.2M).
The company expects adjusted EBITDA positive for full‑year 2025 and to achieve cash flow breakeven in Q4 2025.
Iridex (Nasdaq: IRIX) will release third quarter 2025 financial results and provide a business update after market close on Tuesday, November 11, 2025. Management will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET the same day.
Investors can join by dialing +1-888-596-4144 (US) or +1-646-968-2525 (international) and using Conference ID: 1504499. A live and recorded webcast will be posted on the company’s Investors > Event Calendar page at www.iridex.com.
Iridex Corporation (Nasdaq: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases, has successfully regained compliance with Nasdaq's continued listing requirements. The company had received a non-compliance notice on May 14, 2025, due to falling below the minimum stockholders' equity requirement of $2.5 million based on their Q1 2025 10-Q filing.
On August 27, 2025, Nasdaq formally confirmed that Iridex had regained compliance with Rule 5550(b)(1) following the company's Q2 2025 10-Q filing on August 12, 2025, which demonstrated sufficient stockholders' equity. The compliance matter has been resolved and closed.
Iridex (NASDAQ: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases, reported its Q2 2025 financial results. The company achieved total revenue of $13.6 million, representing 7% year-over-year growth and 14% sequential growth.
Key highlights include Cyclo G6 product family revenue of $3.3 million (flat year-over-year), with 13,100 probes and 35 laser systems sold. Retina product revenue grew 10% year-over-year to $8.0 million. The company reduced operating expenses by 28% and achieved its third consecutive quarter of positive non-GAAP adjusted EBITDA. However, gross margin declined to 34.5% from 40.7% in Q2 2024.
The company reported a net loss of $1.0 million ($0.06 per share) and maintains $6.8 million in cash. For 2025, Iridex aims to achieve cash flow breakeven and positive adjusted EBITDA with revenue consistent with 2024 levels.
Iridex (Nasdaq: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases, has scheduled its second quarter 2025 financial results release for August 12, 2025 after market close.
The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day. Investors can join via phone at +1-888-596-4144 using passcode 2197032, or access the webcast through Iridex's investor relations website.
Iridex Corporation (NASDAQ: IRIX) announced the enrollment of the first patient in the independent DAME Trial, evaluating the combination of MicroPulse technology with anti-VEGF therapy for severe diabetic macular edema (DME). The UK-based study, led by Professor Noemi Lois at Queen's University Belfast, aims to enroll 264 participants across 20 clinical sites.
The trial will assess the clinical efficacy, safety, cost-effectiveness, and patient acceptability of adding subthreshold MicroPulse treatments to anti-VEGF therapy. The study focuses on patients with severe DME, defined by central retinal subfield thickness ≥400 μm. The research is funded by the National Institute for Health Research (NIHR) and utilizes Iridex's IQ 577® laser system with MicroPulse® treatment mode and TxCell® Scanning Delivery Device.
Iridex Corporation (Nasdaq: IRIX), a leader in laser-based medical systems for treating glaucoma and retinal diseases, has scheduled its first quarter 2025 financial results announcement for May 13, 2025, after market close.
The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day. Investors can join the call by dialing +1-888-596-4144 with conference ID: 698002.
A live and recorded webcast of the event will be accessible through the "Event Calendar" page in the "Investors" section of Iridex's website at www.iridex.com.
Iridex (NASDAQ:IRIX) has released preliminary Q1 2025 financial results, showing signs of business stabilization. The company expects total revenue between $11.8-12.0 million, comparable to Q1 2024's $11.8 million.
Key operational metrics include sales of approximately 13,900 Cyclo G6 probes (up from 13,300 year-over-year) and 24 Cyclo G6 Laser Systems (up from 22). Cash and cash equivalents stood at $7.2 million as of March 29, 2025.
The company reports improved financial condition following strategic investment from Novel Inspiration International Co., , with consecutive quarterly revenue increases while reducing operating expenses. Management indicates potential for breakeven or better performance at historical revenue levels, despite exposure to external factors like tariff policy changes.
Iridex (Nasdaq: IRIX), a leading provider of laser-based medical systems for glaucoma and retinal diseases, has announced a strategic vision call scheduled for April 16, 2025. The call will outline the company's strategic direction following Novel's recent strategic investment.
The conference call is set to begin at 2:00 p.m. PT / 5:00 p.m. ET. Investors can participate by dialing 888-596-4144 with conference ID: 9584140. Both a live and recorded webcast will be accessible through the 'Event Calendar' section on Iridex's investor relations website.